EDAP TMS (FOCL)
NASDAQ:FOCL
Want to see FOCL full AI Analyst Report?
FOCL Stock Chart & Stats
$3.49
-$0.15(-5.88%)
At close: 4:00 PM EST
$3.49
-$0.15(-5.88%)
Day’s Range― - ―
52-Week Range$1.21 - $5.24
Previous CloseN/A
VolumeN/A
Average Volume (3M)36.57K
Market Cap
$191.16M
Enterprise Value$196.44M
Total Cash (Recent Filing)$15.01M
Total Debt (Recent Filing)$27.79M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 26, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding37,481,987
10 Day Avg. Volume28,395
30 Day Avg. Volume36,573
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.35
Price to Sales (P/S)1.74
P/FCF Ratio-5.76
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue4.94
Enterprise Value/Gross Profit11.24
Enterprise Value/Ebitda-15.43
Forecast
1Y Price Target
$10.00Price Target Upside186.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.88
Revenue Forecast (FY)$65.20M
Bulls Say, Bears Say
Bulls Say
HIFU Revenue GrowthSustained double-digit capital sales and 78% YoY HIFU revenue growth reflect accelerating commercial adoption and expanding installed base. This durable demand increases recurring consumable/service revenue potential and creates leverage in per-system economics as placements scale over multiple quarters.
Improving Gross MarginsHigher product-level margins, especially HIFU at ~51%, indicate strong unit economics and pricing power. Durable margin expansion supports translating revenue growth into future operating leverage, improving the path to sustained profitability as fixed costs are absorbed by higher volumes.
Clinical & Indication ExpansionRobust clinical evidence (HIFI‑2) and active programs in endometriosis and BPH strengthen clinical credibility and reimbursement prospects across multiple indications. That structural validation expands the addressable market, accelerates physician adoption, and supports durable procedure volume growth and system utilization.
Bears Say
Negative Cash FlowPersistent operating and free cash flow deficits signal structural cash burn that can force frequent external financing. Over the medium term this raises refinancing and dilution risk, constraining the company’s ability to fund scaling, R&D, and international commercialization without recurring capital raises.
Sustained Operating LossesNegative margins and deeply negative EBIT/EBITDA despite revenue gains indicate limited operating leverage at current scale and elevated opex. If operating expense growth outpaces revenue, profitability could remain elusive and hinder durable free cash flow conversion as the company expands.
Dilution / Capital Authorization RiskBroad shareholder authorization to issue equity and instruments creates an explicit pathway for dilution to address cash needs. While it provides financing flexibility, repeated use would erode existing equity value and could weaken long-term returns for current shareholders if used to cover recurring cash shortfalls.
EDAP TMS News
FOCL FAQ
What was EDAP TMS’s price range in the past 12 months?
EDAP TMS lowest stock price was $1.21 and its highest was $5.24 in the past 12 months.
What is EDAP TMS’s market cap?
EDAP TMS’s market cap is $191.16M.
When is EDAP TMS’s upcoming earnings report date?
EDAP TMS’s upcoming earnings report date is Aug 26, 2026 which is in 59 days.
How were EDAP TMS’s earnings last quarter?
EDAP TMS released its earnings results on May 07, 2026. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.205 by -$0.035.
Is EDAP TMS overvalued?
According to Wall Street analysts EDAP TMS’s price is currently Undervalued.
Does EDAP TMS pay dividends?
EDAP TMS does not currently pay dividends.
What is EDAP TMS’s EPS estimate?
EDAP TMS’s EPS estimate is -0.22.
How many shares outstanding does EDAP TMS have?
EDAP TMS has 37,481,987 shares outstanding.
What happened to EDAP TMS’s price movement after its last earnings report?
EDAP TMS reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.205. Following the earnings report the stock price went up 15.716%.
Which hedge fund is a major shareholder of EDAP TMS?
Currently, no hedge funds are holding shares in FOCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EDAP TMS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (186.53% Upside)
$10.00 (186.53% Upside)
Blogger Sentiment
Bullish
FOCL Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $42.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
152.89%
12-Months-Change
Fundamentals
Return on Equity
-148.90%
Trailing 12-Months
Asset Growth
-11.03%
Trailing 12-Months
Company Description
EDAP TMS
EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.
FOCL Earnings Call
Q1 2026
0:00 / 0:00
FOCL Stock 12 Month Forecast
Average Price Target
$10.00
▲(186.53% Upside)
Technical Analysis
Ownership Overview
2.71% Insiders
1.17% Mutual Funds
28.38% Other Institutional Investors
67.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---